Pfizer Inc. (NYSE:PFE) Stock Holdings Lessened by FineMark National Bank & Trust

FineMark National Bank & Trust cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 196,586 shares of the biopharmaceutical company’s stock after selling 15,412 shares during the quarter. FineMark National Bank & Trust’s holdings in Pfizer were worth $5,215,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Charles Schwab Investment Management Inc. increased its stake in Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Pfizer in the fourth quarter worth about $274,694,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Pfizer by 22.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock worth $1,101,713,000 after acquiring an additional 6,977,587 shares in the last quarter. Fisher Asset Management LLC raised its holdings in shares of Pfizer by 79.5% during the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company’s stock valued at $295,760,000 after acquiring an additional 4,938,209 shares during the period. Finally, Van ECK Associates Corp lifted its position in shares of Pfizer by 28.5% in the 4th quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock valued at $564,739,000 after acquiring an additional 4,726,549 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by insiders.

Analysts Set New Price Targets

PFE has been the topic of several recent analyst reports. Bank of America reissued a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Finally, Citigroup dropped their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Price Performance

NYSE:PFE opened at $26.13 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market cap of $148.21 billion, a P/E ratio of 18.53, a PEG ratio of 0.64 and a beta of 0.61. The company has a fifty day moving average price of $26.15 and a 200 day moving average price of $27.02. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.10 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.